Page results
-
Our team deliver care to people with MS and aim to provide specialist services, share information on how to manage symptoms, offer education sessions, medication options and rehabilitation services.
-
Our vascular service has a major emphasis on endovascular (minimally invasive) treatments for vascular diseases, and this approach has largely replaced conventional open vascular surgery at UCLH.
-
Preparations for the festive season are in full swing in the UCLH Charity fundraising team.
-
The department offers a wide range of investigations and treatment for benign and cancerous surgical diseases, with specialisation in lower and upper GI surgery (including for weight loss).
-
The Neurometabolic unit provides a unique range of investigations and clinical laboratory advice encompassing mitochondrial, neurotransmitter, pterin and amino acid disorders.
-
The clinical management of neuromuscular muscle wasting diseases such as motor neuron disease, myasthenia gravis, muscular dystrophy and peripheral neuropathy.
-
Typically, patient care is multidisciplinary led by consultant neuro-ophthalmologists and neurologists.
-
The department is responsible for a wide range of neurophysiological procedures, principally electromyography (EMG) and nerve conduction studies, EMG-guided botulinum toxin (BoTox) injections, electroencephalography (EEG), evoked potentials (EPs) and intra-operative monitoring (IOM)
-
The plasma exchange service at the National Hospital treats patients with neuroimmunological diseases such as Guillain-Barré syndrome and myasthenia gravis.
-
The Same Day Emergency Care Unit (SDEC) is part of the Emergency Services Division at University College Hospital. It is in the same part of the hospital as the Emergency Department, on the ground floor of University College Hospital in the Elizabeth Garrett Anderson Wing.
File results
-
FOI/2022/0386 - Permanent/ International Recruitment for medical and non medical staff
-
FOI/2022/0392 - Replacement of patient trolleys
-
FOI/2022/0393 - COVID-19 patient treatment between 16/03/2020 - 16/06/2020
-
FOI/2022/0399 - Staff networks at the Trust
-
FOI/2022/0402 - Breast Cancer patients (any stage) treatments
-
FOI/2022/0405 - Treatments C1-esterase inhibitor & immunoglobulin treatments
-
FOI/2022/0408 - Date UCLH became smoke-free
-
FOI/2022/0412 - Mental health inpatient facilities
-
FOI/2022/0413 - Head and neck cancer and urothelial cancer patients treatment and clinical trials
-
FOI/2022/0421 - Paediatric autoimmune neuropsychiatric disorders